Merck's Big Play in RNA

Its deal to acquire Sirna puts the spotlight on a Nobel-prize winning medical breakthrough -- and boosts the shares of other biotechs

Merck's (MRK) announcement after the close of trading Oct. 30 that it would acquire Sirna Therapeutics (RNAI) for $1.1 billion struck Wall Street as a vote of confidence in RNA interference (RNAi), a Nobel-Prize winning medical breakthrough that has yet to prove itself commercially.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.